RECRUITING

A Study of Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures

Talk to us

Conditions

Bladder Spasms

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research is being done to find out whether intravenous magnesium is effective in the treatment of bladder spasms after urologic surgery.

Official Title

Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures

Quick Facts

Study Start:2023-07-31
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05806996

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * Are unable to grant informed consent or comply with study procedure.
  2. * Allergy or known sensitivity to magnesium or Renacidin.
  3. * Expected or high risk of bladder extravasation.
  4. * Ongoing atrial fibrillation prior to surgery.
  5. * Are undergoing emergency surgery.
  6. * Are pregnant.
  7. * Known hypermagnesemia.
  8. * Patients with neuromuscular weakness (e.g., Myasthenia gravis) due to magnesium's muscle weakening effect.
  9. * Patients with myocardial compromise or cardiac conduction defects because of magnesium's anti-inotropic effects.
  10. * Patients with renal insufficiency, glomerular filtration rate less than 30, since Magnesium is eliminated by the kidneys resulting in exaggerated rise in serum magnesium.
  11. * Patients with concomitant use of a calcium channel blocker since magnesium sulfate could act synergistically to suppress muscular contractility.

Contacts and Locations

Study Contact

Tami Krpata
CONTACT
507-422-5768
krpata.tami@mayo.edu

Principal Investigator

Gregory Nuttall, MD
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Minnesota
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Gregory Nuttall, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-31
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2023-07-31
Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Bladder Spasms